Indirect immune target

Indirect immune targets refer to a diverse set of molecules that influence immune system activity through secondary mechanisms rather than direct binding to immune cell receptors. These targets often reside within the tissue microenvironment and include metabolic enzymes, growth factors, and stromal components that indirectly regulate the recruitment, activation, and persistence of immune cells (PMID: 30546054). For instance, Indoleamine 2,3-dioxygenase 1 (IDO1) acts as an indirect target by depleting tryptophan, thereby creating a metabolic environment that suppresses T-cell function (PMID: 28848224). Similarly, Vascular Endothelial Growth Factor (VEGF) is considered an indirect immune target because its inhibition can normalize tumor vasculature and reduce the infiltration of myeloid-derived suppressor cells (PMID: 29650535). Therapeutic modulation of these targets aims to overcome extrinsic resistance to immunotherapy by reprogramming the local environment to be more pro-inflammatory or less suppressive. Because the term encompasses a broad functional category rather than a single molecular entity, it is not classified as a specific therapeutic target in pharmacological databases. Instead, it serves as a conceptual grouping for drug discovery efforts focused on the broader context of immune regulation in diseases like cancer and chronic inflammation (PMID: 31048767).

Other names

Indirect immunomodulatorImmune microenvironment targetNon-canonical immune targetExtrinsic immune regulator

Modulation of the immune response through the alteration of the extracellular environment, metabolic pathways, or non-immune cell signaling.